TAZVERIK

This brand name is authorized in Estonia, Japan, United States

Active ingredients

The drug TAZVERIK contains one active pharmaceutical ingredient (API):

1 Tazemetostat UNII 6P89T5M073 - TAZEMETOSTAT HYDROBROMIDE

Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. It is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. It is also used for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation.

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TAZVERIK Film coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX72		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX72

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1814127, 1818761
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291073F1029
Country: US	FDA, National Drug Code	Identifier(s): 72607-100